Objective:

To evaluate the effectiveness of Immunoscore in predicting outcomes and guiding treatment in colorectal cancer (CRC) compared to traditional TNM staging.

Approach:

Key Findings:

• Immunoscore predicts recurrence and survival more accurately than TNM staging or MMR status alone.
• High Immunoscore in stage III colon cancer correlates with improved disease-free and overall survival with adjuvant chemotherapy.
• Low Immunoscore patients show similar outcomes regardless of chemotherapy treatment.
• Immunoscore refines risk stratification beyond MMR status, identifying high-risk subgroups within MSI-high tumors.
• Immunoscore-IC can identify metastatic pMMR CRC patients who may benefit from immune checkpoint inhibitors.

Interpretation:

Immunoscore captures underlying immune biology more effectively than MSI testing, suggesting its potential for improved patient stratification and treatment selection.

Limitations:

• Limited implementation in clinical practice due to reliance on proprietary platforms and cost.
• Technical complexity and need for standardized training hinder widespread use.
• Current tests measure only certain immune cells, not the full immune response.

Conclusion:

Immunoscore represents a significant advancement in immune-informed staging and treatment selection for CRC, with potential for integration into clinical practice and guidelines.

Sources:

• The Journal of Pathology: Clinical Research
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.